A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

Tanaka, Kimihiro; Tokunaga, Eriko; Yamashita, Nami; Taketani, Kenji; Akiyoshi, Sayuri; Morita, Masaru; Maehara, Yoshihiko

doi:10.1007/s00595-013-0765-4

Cited by 4 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although aminoglutethimide (the first-generation aromatase inhibitor) can suppress the estrogen and inhibit only aromatase enzyme, therefore the levels of circulating androgen were found to be not affected due to suppression of estrogens. In addition, because of the side effects and inconvenience of parenteral administration of the first generation, second, and third generation of the aromatase inhibitors such as anastrozole, formestane and letrozole were developed [ 115 ]. Moreover, the third generation of aromatase inhibitors showed a greater response than tamoxifen treatment alone [ 116 , 117 ].…”

Section: Treatments Of Metastatic Breast Cancermentioning

confidence: 99%

Metastatic and triple-negative breast cancer: challenges and treatment options

Al-Mahmood

Sapiezynski

Garbuzenko

et al. 2018

Drug Deliv. and Transl. Res.

398

258

View full text Add to dashboard Cite

The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10–20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.

show abstract

Section: Treatments Of Metastatic Breast Cancermentioning

confidence: 99%

Metastatic and triple-negative breast cancer: challenges and treatment options

Al-Mahmood

Sapiezynski

Garbuzenko

et al. 2018

Drug Deliv. and Transl. Res.

398

258

View full text Add to dashboard Cite

show abstract

“…No cases of grade 3/4 toxicity were observed. Previous studies have also reportedthat AI combined with LHRH agonist is a safe and well-tolerated treatment, with no serious adverse events[12][13][14][15][16][17][18].…”

mentioning

confidence: 79%

“…Although the benefits of ovarian suppression alone in premenopausal patients with breast cancer is still under investigation, the benefit of combined tamoxifen and LHRH agonist treatment was demonstrated in a meta-analysis of four randomized trials comparing this treatment to LHRH agonist administration alone [19]. Moreover, a few studies have shown promising results for AI in combination with LHRH agonist [12][13][14][15][16][17][18], despite concerns that the use of AI alone in premenopausal women could cause ovarian stimulation [9]. In a pro- Our study has several limitations.…”

Section: Discussionmentioning

confidence: 99%

“…The combined results of the TEXT and SOFT trials demonstrated that, compared with tamoxifen, an AI (exemestane) significantly reduced the risk of ORIGINAL ARTICLE 47 recurrence when used as an adjuvant treatment after the suppression of ovarian function. Consequently, there is a growing debate over the role of AI in the treatment of premenopausal patients with MBC [11], and to date, only a few studies have addressed this important issue [12][13][14][15][16][17][18]. Here, we report the clinical outcomes following combined AI and LHRH agonist treatment for premenopausal patients with MBC.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer

Kim¹,

Choi²,

Park

et al. 2018

J Breast Dis

View full text Add to dashboard Cite

Purpose: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC. Methods: We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy. Results: The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity. Conclusion: Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.

show abstract

Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer

et al. 2015

View full text Add to dashboard Cite

The prognosis of the patients with MBC in this series was better than that reported before 2000, which is probably attributable to the use of novel, improved pharmacological agents. For example, luminal-HER2 tumors can be treated using both aromatase inhibitors and trastuzumab. Because of the lower toxicities, it is now possible to administer these agents for longer periods, resulting in better prognoses.

show abstract

A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

Abstract: The combination of an LHRH agonist plus an AI is a treatment option for premenopausal females with HR-positive MBC that can prolong the chemotherapy-free interval and yield effective disease stabilization.

Cited by 4 publications

References 19 publications

Metastatic and triple-negative breast cancer: challenges and treatment options

Metastatic and triple-negative breast cancer: challenges and treatment options

Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer

Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer

Contact Info

Product

Resources

About